PD-L1 positive platelets mediate resistance to immune checkpoint inhibitors in patients with colorectal cancer
Abstract Background Programmed cell death ligand 1 (PD-L1) expression on immune cells is correlated with the efficacy of immune checkpoint inhibitor (ICI) therapy in various types of cancer. Platelets are important components of the tumour microenvironment (TME) and are widely involved in the develo...
Saved in:
| Main Authors: | Jiacheng Li, Jia Liu, Shifeng Yang, Yu Xia, Qingzhe Meng, Biying Sun, Yansong Liu, Bin Zhao, Jiaqi Jin, Hui Xu, Lihong Wang, Pengxia Zhang, Zhuoxin Cheng |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Cell Communication and Signaling |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12964-025-02034-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Enhancing cancer care with improved checkpoint inhibitors
by: Vickram A S, et al.
Published: (2024-10-01) -
Safety and efficacy of PD-1/PD-L1 immune checkpoint inhibitors in patients with pre-treated advanced stage malignant mesothelioma: a systematic review and meta-analysis
by: Amjad Zafar, et al.
Published: (2024-11-01) -
Patient-derived colorectal microtumors predict response to anti-PD-1 therapy
by: Duy T. Nguyen, et al.
Published: (2025-08-01) -
Immune checkpoint inhibitors in metastatic colorectal cancer therapy (a review)
by: P. P. Sorochan, et al.
Published: (2022-07-01) -
Delta‐He as a Novel Predictive and Prognostic Biomarker in Patients With NSCLC Treated With PD–1/PD‐L1 Inhibitors
by: Green Hong, et al.
Published: (2025-04-01)